Several small-molecule KDM1A inhibitors, such as CBB1003 [88], ORY-1001 [89], GSK2879552 [89], ZY0511 [96,97,98], and tranylcypromine/tranylcypromine hemisulfate [95,99], were shown to inhibit CRC cell growth or migration by modulating specific gene or pathway expression in in vitro or in vivo CRC models. The gene discussed is KDM1A; the disease is colorectal carcinoma.